Skip to main content

and
  1. Article

    Open Access

    Ten years after: findings from the medical surveillance program on Health Effects in High-Level Exposure to PCB (HELPcB)

    After the detection of high environmental and occupational exposure to polychlorinated biphenyls (PCBs) in a German recycling company for transformers and capacitors in 2010, the multidisciplinary medical surv...

    Jens Rengelshausen, Isabella Randerath, Thomas Schettgen in Archives of Toxicology (2023)

  2. Article

    Open Access

    Influence on study outcomes of an inpatient study by the behavior of the study staff (PINgPOng): study protocol for a randomized clinical trial

    The placebo effect as the symptom improvement following inert treatments is a fixed component of RCTs to differentiate between specific effects of the tested pharmacological substance from other unspecific eff...

    Martin Coenen, Ulrike Bingel, Matthias Zunhammer, Maria Soledad Berdaguer in Trials (2022)

  3. No Access

    Article

    Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis Approach

    Understanding the effect of oxycodone pharmacokinetics (PK) on µ-opioid receptor binding benefits from an integrated approach to compiling the results of multiple studies. The current pharmacokinetic/pharmacod...

    Anna Dari, Stefan Buller, Michael Gautrois in Clinical Pharmacokinetics (2021)

  4. Article

    Open Access

    How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

    A discussion forum was hosted by the Association for Applied Human Pharmacology (AGAH e.V.) to critically debate how to interpret and optimise the Investigator’s Brochure (IB) for meaningful risk assessment of...

    Jens Rengelshausen in Therapeutic Innovation & Regulatory Science (2021)

  5. Article

    Open Access

    Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials

    A discussion forum was hosted by the German not-for-profit Association for Applied Human Pharmacology (AGAH e.V.) to critically review key eligibility criteria and stop** rules for clinical trials with healt...

    Kerstin Breithaupt-Groegler, Christoph Coch in European Journal of Clinical Pharmacology (2017)

  6. No Access

    Article

    High absolute bioavailability of methylene blue given as an aqueous oral formulation

    Methylene blue (MB) has recently been reevaluated for malaria treatment. With the aim of excluding treatment failures due to low bioavailability, we have investigated the absolute bioavailability of MB given a...

    Ingeborg Walter-Sack, Jens Rengelshausen in European Journal of Clinical Pharmacology (2009)

  7. Article

    Open Access

    Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine

    The development of safe, effective and affordable drug combinations against malaria in Africa is a public health priority. Methylene blue (MB) has a similar mode of action as chloroquine (CQ) and has moreover ...

    Peter E Meissner, Germain Mandi, Boubacar Coulibaly, Steffen Witte in Malaria Journal (2006)

  8. No Access

    Article

    Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very w gestational age

    Pharmacokinetic parameters are important for dose adjustment of aminoglycosides, but they are highly variable in neonates. In this study the pharmacokinetics of a netilmicin loading dose was investigated on th...

    Jens Rengelshausen, Bernd Beedgen in European Journal of Clinical Pharmacology (2006)

  9. Article

    Open Access

    Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]

    Safe, effective and affordable drug combinations against falciparum malaria are urgently needed for the poor populations in malaria endemic countries. Methylene blue (MB) combined with chloroquine (CQ) has bee...

    Peter E Meissner, Germain Mandi, Steffen Witte, Boubacar Coulibaly in Malaria Journal (2005)

  10. No Access

    Article

    Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

    An important information source for pharmacotherapy in populations at risk is drug labelling. We compared the recommendations for patients with renal insufficiency included in German drug labellings with evide...

    Meret Martin-Facklam, Jens Rengelshausen in European Journal of Clinical Pharmacology (2005)

  11. No Access

    Article

    Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria

    The combination of chloroquine and methylene blue is potentially effective for the treatment of chloroquine-resistant malaria caused by Plasmodium falciparum. The aim of this study was to investigate whether met...

    Jens Rengelshausen, Jürgen Burhenne in European Journal of Clinical Pharmacology (2004)

  12. No Access

    Article

    Familiäres Mittelmeerfieber

    Drei türkische Patienten zwischen 23 und 32 Jahren stellten sich mit akuten Abdominalschmerzen und Fieber vor. Bei allen traten seit Jahren diese Beschwerden rezidivierend im Abstand von Wochen auf und sistier...

    Jens Rengelshausen, Michael Rünzi, Ali Canbay, Guido Gerken in Medizinische Klinik (1999)

  13. No Access

    Chapter

    Inhibition of Porcine Renal Ecto-ATP Diphosphohydrolase by Ca2+ Channel Blockers and Neuroleptic Drugs

    Brush-border membrane vesicles (BBMV) from rat, rabbit and pig kidneys have been used to characterize renal ecto-ATPases. In rat1,2 and rabbit renal BBMV3, Mg2+ stimulated enzyme activity better than Ca2+, wherea...

    Jens Rengelshausen, Christa Schweickhardt, Gerhard Burckhardt in Ecto-ATPases (1997)